Graphite Bio (NASDAQ:GRPH – Get Rating) had its value goal lower by equities researchers at Bank of America from $10.00 to $8.00 in a analysis observe issued to buyers on Tuesday, The Fly studies. Bank of America‘s value goal would point out a possible upside of 183.69% from the inventory’s earlier shut.
Individually, Cantor Fitzgerald assumed protection on shares of Graphite Bio in a analysis report on Thursday, September fifteenth. They issued an “chubby” ranking and a $12.00 value goal for the corporate. Two funding analysts have rated the inventory with a maintain ranking and 4 have given a purchase ranking to the inventory. Primarily based on information from MarketBeat, the corporate presently has a median ranking of “Average Purchase” and a median value goal of $12.14.
Graphite Bio Inventory Down 1.1 %
Graphite Bio stock opened at $2.82 on Tuesday. Graphite Bio has a 52-week low of $2.07 and a 52-week excessive of $13.39. The agency has a fifty day transferring common of $3.35 and a 200-day transferring common of $3.27. The agency has a market capitalization of $163.98 million, a P/E ratio of -1.60 and a beta of 0.44.
Graphite Bio (NASDAQ:GRPH – Get Rating) final launched its quarterly earnings information on Wednesday, November ninth. The corporate reported ($0.45) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.04. On common, analysis analysts count on that Graphite Bio will publish -1.88 EPS for the present fiscal 12 months.
Institutional Buyers Weigh In On Graphite Bio
A variety of massive buyers have lately added to or decreased their stakes in GRPH. Renaissance Applied sciences LLC acquired a brand new stake in Graphite Bio throughout the 2nd quarter valued at $2,165,000. Laurion Capital Administration LP acquired a brand new stake in Graphite Bio throughout the 2nd quarter valued at $1,577,000. Vanguard Group Inc. grew its holdings in Graphite Bio by 71.7% throughout the 1st quarter. Vanguard Group Inc. now owns 1,202,755 shares of the corporate’s inventory valued at $6,135,000 after buying a further 502,381 shares within the final quarter. BlackRock Inc. grew its holdings in Graphite Bio by 39.8% throughout the 1st quarter. BlackRock Inc. now owns 1,694,506 shares of the corporate’s inventory valued at $8,642,000 after buying a further 482,238 shares within the final quarter. Lastly, EcoR1 Capital LLC boosted its stake in Graphite Bio by 36.1% throughout the third quarter. EcoR1 Capital LLC now owns 1,582,135 shares of the corporate’s inventory valued at $5,015,000 after buying a further 419,956 shares over the last quarter. 52.51% of the inventory is owned by institutional buyers and hedge funds.
About Graphite Bio
Graphite Bio, Inc, a clinical-stage gene modifying firm, engages in creating therapies for critical and life-threatening ailments in the US. It affords GPH101, a gene-edited autologous hematopoietic stem cell product candidate to instantly right the mutation that causes sickle cell illness and restore regular grownup hemoglobin expression; GPH201 for the therapy of X-linked extreme mixed immunodeficiency syndrome; and GPH301, a product candidate for the therapy of Gaucher illness, a genetic dysfunction that ends in a deficiency within the glucocerebrosidase enzyme.
This immediate information alert was generated by narrative science expertise and monetary information from MarketBeat in an effort to present readers with the quickest and most correct reporting. This story was reviewed by MarketBeat’s editorial staff previous to publication. Please ship any questions or feedback about this story to email@example.com.
Earlier than you take into account Graphite Bio, you will need to hear this.
MarketBeat retains observe of Wall Road’s top-rated and finest performing analysis analysts and the shares they advocate to their shoppers every day. MarketBeat has recognized the five stocks that prime analysts are quietly whispering to their shoppers to purchase now earlier than the broader market catches on… and Graphite Bio wasn’t on the checklist.
Whereas Graphite Bio at the moment has a “Average Purchase” ranking amongst analysts, top-rated analysts consider these 5 shares are higher buys.